SCHEMBL4176003

SCHEMBL4176003

NCc1cc2cccc(Cl)c2nc1-c1cc(F)ccc1C(F)(F)F

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.39
PIK3CD O00329 4/20 0.36
HSD11B1 P28845 1/20 0.35
NR1H2 P55055 5/20 0.35
NR1H3 Q13133 3/20 0.35
NR1I2 O75469 1/20 0.35
NR3C1 P04150 1/20 0.35
AR P10275 1/20 0.35
RXRA P19793 1/20 0.35
IDO1 P14902 2/20 0.35
TRPA1 O75762 1/20 0.34
SCN9A Q15858 2/20 0.34
NT5E P21589 1/20 0.32
CNR1 P21554 1/20 0.32
CNR2 P34972 1/20 0.32
PNMT P11086 1/20 0.32
DPP4 P27487 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10251720 0.89 P2RX7 (0.40) P2RX7PIK3CDHSD11B1NR1H2NR1H3
SCHEMBL4169435 0.88 P2RX7 (0.39) P2RX7PIK3CDHSD11B1NR1H2NR1H3
Hydrochloric Acid SCHEMBL4178728 0.88 P2RX7 (0.39) P2RX7PIK3CDHSD11B1NR1H2NR1H3
SCHEMBL4174726 0.87 PIK3CD (0.39) PIK3CDPNMTDPP4
SCHEMBL21705922 0.85 DPP4 (0.36) PIK3CDPNMTDPP4
SCHEMBL27781269 0.84 P2RX7 (0.36) P2RX7PIK3CDHSD11B1NR1H2NR1H3
SCHEMBL16270360 0.83 PIK3CD (0.35) PIK3CDPNMTDPP4
SCHEMBL4170606 0.81 PIK3CD (0.46) PIK3CDNR3C1DPP4
SCHEMBL4172530 0.80 HSD11B1 (0.36) P2RX7HSD11B1NR1H2NR1H3NR1I2
SCHEMBL12014804 0.79 NR3C1 (0.40) P2RX7PIK3CDHSD11B1NR3C1SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200048265-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2020-02-13 US disclosed
US-20200048265-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2020-02-13 US disclosed
US-20180105532-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2018-04-19 US disclosed
US-20180105532-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2018-04-19 US disclosed
US-20180105532-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2018-04-19 US disclosed
US-9873701-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2018-01-23 US disclosed
US-9873701-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2018-01-23 US disclosed
US-9873701-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2018-01-23 US disclosed
EP-3045458-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES Amgen, Inc (US) 2016-07-20 EP disclosed
EP-3045458-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES Amgen, Inc (US) 2016-07-20 EP disclosed
US-20120220585-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2012-08-30 US disclosed
US-8193199-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2012-06-05 US disclosed
US-8193199-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2012-06-05 US disclosed
US-8193199-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2012-06-05 US disclosed
EP-2137186-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES Amgen Inc. (US) 2009-12-30 EP disclosed
US-20090137581-A1 Heterocyclic compounds and their uses AMGEN INC. 2009-05-28 US disclosed
US-20090137581-A1 Heterocyclic compounds and their uses AMGEN INC. 2009-05-28 US disclosed
US-20090137581-A1 Heterocyclic compounds and their uses AMGEN INC. 2009-05-28 US disclosed
WO-2008118468-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2008-10-02 WO disclosed
WO-2008118468-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2008-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200048265-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, BCL9, MALT1 P2RX7 1736/4885PIK3CD 16/4885HSD11B1 2935/4885
US-20090137581-A1 Heterocyclic compounds and their uses MCL1, BCL9, MALT1 P2RX7 1736/4885PIK3CD 16/4885HSD11B1 2935/4885
US-20180105532-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, BCL9, MALT1 P2RX7 1736/4885PIK3CD 16/4885HSD11B1 2935/4885
US-20120220585-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, BCL9, MALT1 P2RX7 1736/4885PIK3CD 16/4885HSD11B1 2935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.